These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 35759013)

  • 1. Early use of fingolimod is associated with better clinical outcomes in relapsing-remitting multiple sclerosis patients.
    Cannizzaro M; Ferré L; Clarelli F; Giordano A; Sangalli F; Colombo B; Comi G; Moiola L; Martinelli V; Filippi M; Esposito F
    J Neurol; 2022 Oct; 269(10):5596-5605. PubMed ID: 35759013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness and baseline factors associated to fingolimod response in a real-world study on multiple sclerosis patients.
    Esposito F; Ferrè L; Clarelli F; Rocca MA; Sferruzza G; Storelli L; Radaelli M; Sangalli F; Moiola L; Colombo B; Martinelli Boneschi F; Comi G; Filippi M; Martinelli V
    J Neurol; 2018 Apr; 265(4):896-905. PubMed ID: 29435643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early evidence of disease activity during fingolimod predicts medium-term inefficacy in relapsing-remitting multiple sclerosis.
    Ferrè L; Mogavero A; Clarelli F; Moiola L; Sangalli F; Colombo B; Martinelli V; Comi G; Filippi M; Esposito F
    Mult Scler; 2021 Aug; 27(9):1374-1383. PubMed ID: 32975468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term outcome in multiple sclerosis patients treated with fingolimod.
    Lattanzi S; Rocchi C; Danni M; Taffi R; Cerqua R; Carletti S; Silvestrini M
    Mult Scler Relat Disord; 2020 Oct; 45():102416. PubMed ID: 32721897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical effectiveness of reduced fingolimod dose in relapsing remitting multiple sclerosis-a Portuguese cohort.
    Ramos-Lopes J; Batista S; Barradas P; Campelo I; Correia I; Nunes C; Macário C; Sousa L
    Neurol Sci; 2021 Mar; 42(3):1039-1043. PubMed ID: 32719903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antigen-shift in varicella-zoster virus-specific T-cell immunity over the course of Fingolimod-treatment in relapse-remitting multiple sclerosis patients.
    Matko S; Akgün K; Tonn T; Ziemssen T; Odendahl M
    Mult Scler Relat Disord; 2020 Feb; 38():101859. PubMed ID: 31855843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study.
    Comi G; Pozzilli C; Morra VB; Bertolotto A; Sangalli F; Prosperini L; Carotenuto A; Iaffaldano P; Capobianco M; Colombo D; Nica M; Rizzoli S; Trojano M
    Neurol Sci; 2020 Oct; 41(10):2843-2851. PubMed ID: 32318950
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cladribine tablets versus other disease-modifying oral drugs in achieving no evidence of disease activity (NEDA) in multiple sclerosis-A systematic review and network meta-analysis.
    Bartosik-Psujek H; Kaczyński Ł; Górecka M; Rolka M; Wójcik R; Zięba P; Kaczor M
    Mult Scler Relat Disord; 2021 Apr; 49():102769. PubMed ID: 33516133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral therapies for treatment of relapsing-remitting multiple sclerosis in Austria: a 2-year comparison using an inverse probability weighting method.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    J Neurol; 2020 Jul; 267(7):2090-2100. PubMed ID: 32246251
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term comparative analysis of no evidence of disease activity (NEDA-3) status between multiple sclerosis patients treated with natalizumab and fingolimod for up to 4 years.
    Guerra T; Caputo F; Orlando B; Paolicelli D; Trojano M; Iaffaldano P
    Neurol Sci; 2021 Nov; 42(11):4647-4655. PubMed ID: 33677753
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Half-dose fingolimod for treating relapsing-remitting multiple sclerosis: Observational study.
    Zecca C; Merlini A; Disanto G; Rodegher M; Panicari L; Romeo MAL; Candrian U; Messina MJ; Pravatà E; Moiola L; Stefanin C; Ghezzi A; Perrone P; Patti F; Comi G; Gobbi C; Martinelli V
    Mult Scler; 2018 Feb; 24(2):167-174. PubMed ID: 28273776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. BEST-MS: A prospective head-to-head comparative study of natalizumab and fingolimod in active relapsing MS.
    Cohen M; Mondot L; Bucciarelli F; Pignolet B; Laplaud DA; Wiertlewski S; Brochet B; Ruet A; Defer G; Derache N; Vermersch P; Zephir H; Debouverie M; Mathey G; Berger E; Cappé C; Labauge P; Carra C; De Seze J; Bigaut K; Brassat D; Lebrun-Frenay C
    Mult Scler; 2021 Sep; 27(10):1556-1563. PubMed ID: 33124504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effectiveness of interferon beta versus glatiramer acetate and natalizumab versus fingolimod in a Polish real-world population.
    Kapica-Topczewska K; Tarasiuk J; Collin F; Brola W; Chorąży M; Czarnowska A; Kwaśniewski M; Bartosik-Psujek H; Adamczyk-Sowa M; Kochanowicz J; Kułakowska A
    PLoS One; 2019; 14(10):e0223863. PubMed ID: 31647829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative discontinuation, effectiveness, and switching practices of dimethyl fumarate and fingolimod at 36-month follow-up.
    Vollmer B; Ontaneda D; Harris H; Nair K; Bermel RA; Corboy JR; Fox RJ; Vollmer T; Cohen JA; Alvarez E; Hersh CM
    J Neurol Sci; 2019 Dec; 407():116498. PubMed ID: 31644992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basal vitamin D levels and disease activity in multiple sclerosis patients treated with fingolimod.
    Ferre' L; Clarelli F; Sferruzza G; Rocca MA; Mascia E; Radaelli M; Sangalli F; Dalla Costa G; Moiola L; Aboulwafa M; Martinelli Boneschi F; Comi G; Filippi M; Martinelli V; Esposito F
    Neurol Sci; 2018 Aug; 39(8):1467-1470. PubMed ID: 29756179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry.
    Guger M; Enzinger C; Leutmezer F; Kraus J; Kalcher S; Kvas E; Berger T;
    J Neurol; 2019 Nov; 266(11):2672-2677. PubMed ID: 31312958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Previous treatment influences fingolimod efficacy in relapsing-remitting multiple sclerosis: results from an observational study.
    Baldi E; Guareschi A; Vitetta F; Senesi C; Curti E; Montepietra S; Simone AM; Immovilli P; Caniatti L; Tola MR; Pesci I; Montanari E; Sola P; Granella F; Motti L; Ferraro D
    Curr Med Res Opin; 2014 Sep; 30(9):1849-55. PubMed ID: 24831186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab.
    Pfeuffer S; Rolfes L; Ingwersen J; Pul R; Kleinschnitz K; Korsen M; Räuber S; Ruck T; Schieferdecker S; Willison AG; Aktas O; Kleinschnitz C; Hartung HP; Kappos L; Meuth SG
    Neurol Neuroimmunol Neuroinflamm; 2023 May; 10(3):. PubMed ID: 37041077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fingolimod versus natalizumab in patients with relapsing remitting multiple sclerosis: a cost-effectiveness and cost-utility study in Iran.
    Rezaee M; Izadi S; Keshavarz K; Borhanihaghighi A; Ravangard R
    J Med Econ; 2019 Apr; 22(4):297-305. PubMed ID: 30561242
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
    Weinstock-Guttman B; Medin J; Khan N; Korn JR; Lathi E; Silversteen J; Calkwood J; Silva D; Zivadinov R;
    CNS Drugs; 2018 Jan; 32(1):75-84. PubMed ID: 29270772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.